IMR Press / RCM / Volume 24 / Issue 2 / DOI: 10.31083/j.rcm2402063
Open Access Review
Noncoding RNAs and Cardiac Fibrosis
Show Less
1 Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, 650000 Kunming, Yunnan, China
*Correspondence: pengyunzhu0308@163.com (Yunzhu Peng)
Rev. Cardiovasc. Med. 2023, 24(2), 63; https://doi.org/10.31083/j.rcm2402063
Submitted: 3 September 2022 | Revised: 7 November 2022 | Accepted: 15 November 2022 | Published: 14 February 2023
(This article belongs to the Section Molecular and Cellular Cardiology)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Myocardial fibrosis is a common pathological feature of various terminal cardiovascular diseases. Progressive fibrosis is the pathological basis for the development and progression of many cardiac arrhythmias and heart failure. There are no effective reversal drugs for myocardial fibrosis due to the lack of understanding of the molecular mechanisms. Noncoding RNAs, a class of RNAs that do not function in coding proteins, have been found to be intimately involved in the life cycle of cardiomyocyte differentiation, transcription and apoptosis and are important regulators of cardiovascular disease. An increasing number of studies have shown that noncoding RNAs regulate the proliferation and transformation of cardiac fibroblasts through related signaling pathways and can be used as potential biomarkers and novel therapeutic targets for cardiac fibrosis. This article reviews the relationship between noncoding RNAs and cardiac fibrosis.

Keywords
non-coding RNAs
myocardial fibrosis
biomarker
gene regulation
molecular mechanism
Funding
82160439/National Nature of Science Foundation of China
202001AY070001-028/Basic Research Plan Project of Yunnan Provincial Science and Technology Department
Figures
Fig. 1.
Share
Back to top